Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Notes Payables (2022 - 2024)

Historic Notes Payables for Mereo BioPharma (MREO) over the last 2 years, with Q4 2024 value amounting to $5.5 million.

  • Mereo BioPharma's Notes Payables changed N/A to $5.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.5 million, marking a year-over-year change of. This contributed to the annual value of $5.5 million for FY2024, which is N/A changed from last year.
  • As of Q4 2024, Mereo BioPharma's Notes Payables stood at $5.5 million.
  • Mereo BioPharma's Notes Payables' 5-year high stood at $13.3 million during Q4 2022, with a 5-year trough of $4.6 million in Q1 2024.